What is it about?
Generic imatinib has recently been approved for chronic myeloid leukemia in Canada and the European Union (EU). There are anecdotal concerns of reduced efficacy related to generic vs. brand name imatinib.
Featured Image
Why is it important?
Overall, anecdotal concerns appear to be unfounded for generic imatinib approved in Canada and the EU. There is no evidence that these generic imatinib products are less effective than brand name imatinib.
Read the Original
This page is a summary of: Clinical efficacy of generic imatinib, Journal of Oncology Pharmacy Practice, February 2014, SAGE Publications,
DOI: 10.1177/1078155214522143.
You can read the full text:
Contributors
The following have contributed to this page
